Boehringer Ingelheim Strikes Regenerative Med R&D Deal

The latest stories trending on MedCity News.

Editor's Pick

Top Story Boehringer Ingelheim Strikes Regenerative Med R&D Deal Spanning MASH & More Liver Diseases The first FDA-approved MASH drug doesn't treat patients with liver cirrhosis. A new Boehringer Ingelheim/Ochre Bio collaboration is researching regenerative medicines that could treat patients in this most advanced stage of the fatty liver disease.   Sponsored Content A Deep-Dive into Specialty Pharma Presented by PurpleLab A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed "orphan" diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS. Learn More. Unlock New Opportunities in Healthcare Innovation Don't miss this exciting opportunity to connect with top minds and entrepreneurs in healthcare. MedCity INVEST is a boutique networking event that includes panel discussions around some of the hottest topics in healthcare transformation, a startup pitch contest, a workshop on government funding for startups and ample networking opportunities. Save $100 NOW, Offer Ends 4/26

Featured News

Neurodivergent Masking: A Hidden Contributor to the $2-Trillion Burnout Crisis It can be tiring pretending to be someone you're not. For many neurodivergent people at work, this is an everyday reality — and it's burning them out. Which Medtech Startups Will Take Part in the MedCity INVEST Pitch Perfect Contest? The diagnostics/medical device track focuses on cardiology this year. Boehringer Ingelheim Strikes Regenerative Med R&D Deal Spanning MASH & More Liver Diseases The first FDA-approved MASH drug doesn't treat patients with liver cirrhosis. A new Boehringer Ingelheim/Ochre Bio collaboration is researching regenerative medicines that could treat patients in this most advanced stage of the fatty liver disease. Why the Commonwealth Fund Created a Task Force for Employer-Sponsored Insurance The Commonwealth Fund recently launched the National Task Force on the Future Role of Employers in the U.S. Health System. In 2025, the task force will release a blueprint of actionable recommendations on how employers can improve their coverage. MedCity FemFwd: What Needs To Happen to Improve Preeclampsia Rates? In this episode, we're joined by John Auerbach, senior vice president of federal health at consulting firm ICF. He discusses rising preeclampsia rates and how stakeholders need to act.

Resources

MedCity Debunked: Change Healthcare Cybersecurity Attack, 23andMe Relevance and Startup Tips In this month's episode, we talk about the massive cyberattack at Change Healthcare that brought the healthcare payment processing clearinghouse to its knees. How were providers, patients, pharmacies, and health systems affected? We also talk about 23AndMe and its relevance in the marketplace. Finally, as a journalist and investor, we offer advice to startups on what is a turn-off for us.  Watch Now

MedCity News • PO Box 901 • New York, NY unsubscribe